US Patent 11180732 Amniotic fluid cell-derived extracellular matrix and uses thereof
Patent 11180732 was granted and assigned to Stembiosys, Inc. on November, 2021 by the United States Patent and Trademark Office.
All edits
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+286 characters)
Article
Patent abstract
Disclosed is a cell-derived extracellular matrix (ECM) derived in vitro from cells isolated from amniotic fluid, and methods of use for the isolation, maintenance, and proliferation of adherent cells including stem cells, as well as for the differentiation of stem cells.
Edits on 10 Oct, 2023
Golden AI
Edits made to:
Infobox (+3 properties)
Infobox
Patent Inventor Names
Edward S. Griffey0
Mary Navarro0
Travis Block0
Edits on 22 Jul, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 23 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
0
Current Assignee
0
Patent Jurisdiction
Patent Number
111807320
Date of Patent
November 23, 2021
0Patent Application Number
165925390
Date Filed
October 3, 2019
0Official Website
Patent Primary Examiner
Edits on 17 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 25 Nov, 2021
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 11180732 Amniotic fluid cell-derived extracellular matrix and uses thereof
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11180732
Date of patent
November 23, 2021
Patent application number
16592539
Date Filed
October 3, 2019
Patent primary examiner
Find more entities like US Patent 11180732 Amniotic fluid cell-derived extracellular matrix and uses thereof
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
